Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Barbara Ann Karmanos Cancer Institute
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02620865CT.gov BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | — | Completed | — | — | — |
NCT00669734CT.gov Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | — | Active Not Recruiting | — | — | — |
NCT00028496CT.gov Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sargramostim (this asset) | Barbara Ann Karmanos Cancer Institute | P1/2 | B · 60 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Docetaxel | Bristol-Myers Squibb | P2 | BBB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Sargramostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P3 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
| Chronic Myeloid Leukemia | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sargramostim in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sargramostim-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →